Genmab A/S (GE9.DE)
| Previous close | 331.00 |
| Open | 331.00 |
| Bid | 0.00 x N/A |
| Ask | 0.00 x N/A |
| Day's range | 331.00 - 331.00 |
| 52-week range | 3.96 - 353.50 |
| Volume | |
| Avg. volume | 3 |
| Market cap | 21.663B |
| Beta (5Y monthly) | 0.81 |
| PE ratio (TTM) | 68.12 |
| EPS (TTM) | 4.86 |
| Earnings date | 01 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
GlobeNewswireTransactions in Connection with Share Buy-back Program
Company Announcement COPENHAGEN, Denmark; June 17, 2024 – Genmab A/S (Nasdaq: GMAB). On March 15, 2024, Genmab announced the initiation of a share buy-back program to repurchase up to DKK 3.5 billion worth of shares. The share buy-back program is expected to be completed no later than December 16, 2024. The following transactions were executed under the program from June 10, 2024, to June 14, 2024: Trading PlatformNo. of sharesAverage price (DKK)Total value (DKK)Accumulated through last announce
- GlobeNewswire
Grant of Restricted Stock Units and Warrants to Employees in Genmab
Company Announcement COPENHAGEN, Denmark; June 12, 2024 – Genmab A/S (Nasdaq: GMAB) announced today that the Board decided to grant 15,711 restricted stock units and 16,052 warrants to employees of the Company and the Company's subsidiaries. Each restricted stock unit is awarded cost-free and provides the owner with a conditional right to receive one share in Genmab A/S of nominally DKK 1. The fair value of each restricted stock unit is equal to the closing market price on the date of grant of o
- GlobeNewswire
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
Company Announcement COPENHAGEN, Denmark; June 11, 2024 – Genmab A/S (Nasdaq: GMAB) - In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523, this document discloses the data of the transactions made in Genmab A/S (Nasdaq: GMAB) by managerial employees and their closely associated persons. The company’s managerial employees and their closely associated persons have given Genmab A/S power of attorney on their behalf to publish trading in Genm
